{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "section-63", "type": "clause", "offset": [29, 40]}], "samples": [{"hash": "1mqWkV876Xe", "uri": "/contracts/1mqWkV876Xe#development-milestone-payments", "label": "License Agreement (Indivior PLC)", "score": 32.388092041, "published": true}, {"hash": "d4wj7lDwfls", "uri": "/contracts/d4wj7lDwfls#development-milestone-payments", "label": "License Agreement (Indivior PLC)", "score": 32.1854896545, "published": true}, {"hash": "3h9UZnRUFDy", "uri": "/contracts/3h9UZnRUFDy#development-milestone-payments", "label": "License Agreement (Addex Therapeutics Ltd.)", "score": 30.9575634003, "published": true}], "size": 11, "snippet": "has the meaning set forth in Section 6.3.", "hash": "603d8771bc7814c7e732dff2d8fd7e38", "id": 1}, {"snippet_links": [{"key": "section-1021", "type": "clause", "offset": [29, 43]}, {"key": "development-milestone-events-and-payments", "type": "clause", "offset": [45, 86]}], "samples": [{"hash": "4Yx3qq6AOEI", "uri": "/contracts/4Yx3qq6AOEI#development-milestone-payments", "label": "Collaboration and License Agreement (Kiniksa Pharmaceuticals, Ltd.)", "score": 33.3394927979, "published": true}, {"hash": "3f9yxkjbxJ3", "uri": "/contracts/3f9yxkjbxJ3#development-milestone-payments", "label": "License and Collaboration Agreement (Zai Lab LTD)", "score": 33.1615333557, "published": true}, {"hash": "3LpWFHJ0YIi", "uri": "/contracts/3LpWFHJ0YIi#development-milestone-payments", "label": "Collaboration and License Agreement (ImmunoGen, Inc.)", "score": 32.1622161865, "published": true}], "size": 10, "snippet": "has the meaning set forth in Section 10.2.1 (Development Milestone Events and Payments).", "hash": "d2b92d041866be2e1c05c3e9b7cd4e70", "id": 2}, {"snippet_links": [{"key": "section-64", "type": "clause", "offset": [36, 47]}], "samples": [{"hash": "4FqvSGxqm5s", "uri": "/contracts/4FqvSGxqm5s#development-milestone-payments", "label": "Collaboration Agreement (Receptos, Inc.)", "score": 24.2881584167, "published": true}, {"hash": "i76fnZGQaKo", "uri": "/contracts/i76fnZGQaKo#development-milestone-payments", "label": "Collaboration Agreement (Receptos, Inc.)", "score": 24.2553043365, "published": true}, {"hash": "3DBlbH5SLaK", "uri": "/contracts/3DBlbH5SLaK#development-milestone-payments", "label": "Collaboration Agreement (Receptos, Inc.)", "score": 24.1184120178, "published": true}], "size": 7, "snippet": "shall have the meaning set forth in Section 6.4.", "hash": "5bb0af468061bdcda54f9c0ee07d829c", "id": 3}, {"snippet_links": [{"key": "set-out", "type": "definition", "offset": [16, 23]}], "samples": [{"hash": "5GQWzh4eboZ", "uri": "/contracts/5GQWzh4eboZ#development-milestone-payments", "label": "Third Deed of Amendment to Share Purchase Agreement (Metsera, Inc.)", "score": 34.8631057739, "published": true}, {"hash": "cAcUWz3P8IN", "uri": "/contracts/cAcUWz3P8IN#development-milestone-payments", "label": "Second Deed of Amendment to the Share Purchase Agreement (Metsera, Inc.)", "score": 34.0253257751, "published": true}, {"hash": "cw1ryrn0VZS", "uri": "/contracts/cw1ryrn0VZS#development-milestone-payments", "label": "Second Deed of Amendment to the Share Purchase Agreement (Metsera, Inc.)", "score": 33.9459266663, "published": true}], "size": 5, "snippet": "has the meaning set out in Paragraph 2.2;", "hash": "2c4144b21405596a33156bddb6bbfc3c", "id": 4}, {"snippet_links": [{"key": "set-out", "type": "definition", "offset": [30, 37]}, {"key": "product-schedule", "type": "definition", "offset": [56, 72]}], "samples": [{"hash": "4IiuNuFcPsq", "uri": "/contracts/4IiuNuFcPsq#development-milestone-payments", "label": "Termination Agreement", "score": 34.2528610229, "published": true}, {"hash": "e303LJIp7X1", "uri": "/contracts/e303LJIp7X1#development-milestone-payments", "label": "Master Licence and Supply Agreement (Alvotech)", "score": 32.5249824524, "published": true}], "size": 2, "snippet": "for a Product has the meaning set out in the applicable Product Schedule;", "hash": "0e243edc4cd28edfa3977432812a5f39", "id": 5}, {"snippet_links": [{"key": "schedule-2", "type": "definition", "offset": [38, 48]}], "samples": [{"hash": "aGQDhKZv6uF", "uri": "/contracts/aGQDhKZv6uF#development-milestone-payments", "label": "Licence and Supply Agreement (CARGO Therapeutics, Inc.)", "score": 32.8453102112, "published": true}, {"hash": "jqRpLVNXs7D", "uri": "/contracts/jqRpLVNXs7D#development-milestone-payments", "label": "Licence and Supply Agreement (Cabaletta Bio, Inc.)", "score": 31.2053394318, "published": true}], "size": 2, "snippet": "shall have the meaning given to it in Schedule 2;", "hash": "363317319f1e91c1e4a0eb12176cf0a6", "id": 6}, {"snippet_links": [{"key": "all-revenues", "type": "clause", "offset": [6, 18]}, {"key": "milestone-payments", "type": "clause", "offset": [38, 56]}, {"key": "research-and-development-fees", "type": "clause", "offset": [61, 90]}, {"key": "in-respect-of", "type": "definition", "offset": [92, 105]}, {"key": "to-the-extent", "type": "clause", "offset": [142, 155]}, {"key": "costs-of", "type": "clause", "offset": [231, 239]}, {"key": "regulatory-approval", "type": "definition", "offset": [279, 298]}, {"key": "pursuant-to-a", "type": "definition", "offset": [339, 352]}, {"key": "development-plan", "type": "clause", "offset": [373, 389]}, {"key": "amounts-received", "type": "definition", "offset": [412, 428]}, {"key": "sale-of-shares", "type": "definition", "offset": [438, 452]}, {"key": "the-capital-stock", "type": "clause", "offset": [456, 473]}, {"key": "current-market", "type": "definition", "offset": [502, 516]}, {"key": "license-fees", "type": "clause", "offset": [539, 551]}, {"key": "the-fair-market-value", "type": "clause", "offset": [556, 577]}, {"key": "other-consideration", "type": "definition", "offset": [585, 604]}, {"key": "received-by", "type": "definition", "offset": [619, 630]}, {"key": "an-event", "type": "clause", "offset": [790, 798]}, {"key": "passage-of-time", "type": "clause", "offset": [883, 898]}, {"key": "net-sales-of-licensed-products", "type": "definition", "offset": [991, 1021]}], "samples": [{"hash": "j0jEX7UKqj8", "uri": "/contracts/j0jEX7UKqj8#development-milestone-payments", "label": "Assignment of License Agreement (Accelerated Pharma, Inc.)", "score": 27.8336753845, "published": true}], "size": 2, "snippet": "means all revenues, receipts, monies, milestone payments and research and development fees (in respect of research and development fees. only to the extent that same are in excess of reimbursement for the direct costs and Indirect Costs of research and development or pursuit of Regulatory Approval undertaken by Poniard or its Affiliates pursuant to a written research or development plan), payments (including amounts received from the sale of shares in the capital stock of Poniard in excess of the Current Market Nee for such shares), license fees and the fair market value of all other consideration, collected or received by Poniard or its Affiliates whether by way of cash, equity, credit or any barter, benefit, advantage, or concession, that are contingent upon the achievement of an event or objective pursuant to a written research or development plan, and not merely the passage of time, and shall exclude amounts collected or received by Poniard or its Affiliates on account of Net Sales of Licensed Products;", "hash": "619c6f12612ffe936fff28d1b1416fab", "id": 7}, {"snippet_links": [{"key": "section-521", "type": "clause", "offset": [36, 49]}], "samples": [{"hash": "6w0E2tStRUF", "uri": "/contracts/6w0E2tStRUF#development-milestone-payments", "label": "License and Research Collaboration Agreement (Opko Health, Inc.)", "score": 34.3333320618, "published": true}], "size": 2, "snippet": "shall have the meaning set forth in Section 5.2.1.", "hash": "d6c57d01efcd79f92da0778977877bbe", "id": 8}, {"snippet_links": [{"key": "defined-in-section", "type": "clause", "offset": [3, 21]}], "samples": [{"hash": "2Gh5NM8MSEQ", "uri": "/contracts/2Gh5NM8MSEQ#development-milestone-payments", "label": "Exclusive License Agreement (CymaBay Therapeutics, Inc.)", "score": 28.2224502563, "published": true}], "size": 2, "snippet": "is defined in Section 5.2.3.", "hash": "4c1fded169365b8e0c685f424fe945ba", "id": 9}, {"snippet_links": [{"key": "payments-to-be-made", "type": "clause", "offset": [10, 29]}, {"key": "development-milestones", "type": "clause", "offset": [94, 116]}], "samples": [{"hash": "lARsxsBrgyC", "uri": "https://www.sec.gov/Archives/edgar/data/1789972/000095017025104551/cgem-ex10_1.htm", "label": "License Agreement (Cullinan Therapeutics, Inc.)", "score": 24.597536087, "published": false}], "size": 1, "snippet": "means the payments to be made by Cullinan to Genrix upon the achievement of the corresponding Development Milestones as set forth in Section \u200e8.3(a) (Development Milestones).", "hash": "82393fcc9e2ff07900e8df04fc329298", "id": 10}], "next_curs": "CmsSZWoVc35sYXdpbnNpZGVyY29udHJhY3RzckcLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiInZGV2ZWxvcG1lbnQtbWlsZXN0b25lLXBheW1lbnRzIzAwMDAwMDBhDKIBAmVuGAAgAA==", "definition": {"title": "Development Milestone Payments", "size": 49, "snippet": "has the meaning set forth in Section 6.3.", "id": "development-milestone-payments", "examples": ["All <strong>Development Milestone Payments</strong> shall be non-refundable and noncreditable.", "Licensee shall keep, and shall require its Affiliates and Sublicensees to keep, accurate records (together with supporting documentation) of sales of Licensed Products and Licensed Processes as appropriate to determine the amount of royalties, Sublicense Payments, Product <strong>Development Milestone Payments</strong> and other monies due to TSRI hereunder, as well as records regarding the calculations of royalty offsets and Combination Products.", "No additional <strong>Development Milestone Payments</strong> will be made for any subsequent achievement of such Development Milestone Event.", "Notwithstanding anything to the contrary in this Agreement, <strong>Development Milestone Payments</strong> shall only be owed pursuant to this Section 5.4.1 for those Agreement PDCs and Licensed Products of which the manufacture or sale is covered by a Valid Claim.", "If a Development Milestone Event for a Target is skipped (i.e., a later Development Milestone Event for a Target is payable before the achievement of an earlier Development Milestone Event for such Target), then the <strong>Development Milestone Payments</strong> for such earlier-listed and skipped Development Milestone Events for such Target will be deemed to have been achieved upon the achievement of the subsequent Development Milestone Event; [***].", "Notwithstanding any other provision of this Agreement, each series of <strong>Development Milestone Payments</strong> will be payable only once with respect to the specified Licensed Target, notwithstanding the number of Licensed Products (or the number of times a Licensed Product) may achieve the applicable Development Milestone Event.", "For the avoidance of doubt, in the event that the first Licensed Product should reach one milestone but not the next, then Genocea shall make such <strong>Development Milestone Payments</strong> due for the second Licensed Product to reach this next Development Milestone.", "If the auditor finds overpayment by Licensee, then Licensee shall have the right to deduct the overpayment from any future <strong>Development Milestone Payments</strong>, Commercial Milestone Payments, Royalties or Sublicense Income due to Penn by Licensee or, if no such future <strong>Development Milestone Payments</strong>, Commercial Milestone Payments, Royalties or Sublicense Income are payable, then Penn shall refund the overpayment to Licensee within [*] after Penn receives the audit report.", "Each Ophthalmic Development Milestone Payment shall be payable only on the first occurrence of the applicable Ophthalmic Development Milestone Event for each of the [***] Ophthalmic Targets, and none of the Ophthalmic <strong>Development Milestone Payments</strong> shall be payable more than once with respect to an Ophthalmic Target, regardless of the number of Ophthalmic Products Developed or Commercialized.", "For the avoidance of doubt, in the event this Agreement is terminated in its entirety in connection with an RP Default, the Initial License Fees, <strong>Development Milestone Payments</strong>, Commercial Milestone Payments and Royalties with respect to Products Directed To a Lilly Target Pair that was the subject of a Research Plan under which no RP Default occurred shall not be reduced."], "related": [["development-milestone-payment", "Development Milestone Payment", "Development Milestone Payment"], ["development-milestone", "Development Milestone", "Development Milestone"], ["milestone-payment", "Milestone Payment", "Milestone Payment"], ["development-milestone-event", "Development Milestone Event", "Development Milestone Event"], ["milestone-payments", "Milestone Payments", "Milestone Payments"]], "related_snippets": [], "updated": "2026-04-02T05:49:26+00:00"}, "json": true, "cursor": ""}}